We are delighted to announce the 2018 NLCFN Annual Conference will be held on 1-2 November at The International Centre, Telford.
The NLCFN conference is renowned for being embedded in day-to-day clinical practice and for welcoming delegates with its reinvigorating and friendly atmosphere. It offers busy healthcare professionals the chance to recharge their batteries by interacting with like-minded colleagues and learning from the experts about the latest developments and treatments specific to the profession.
This year's conference aims to inspire hard working delegates such as yourself to explore the challenges and threats we are working under and explore new ways of working with patients and colleagues in this changing landscape. Our conference promises hope for the future and will explore the latest in lung cancer diagnosis, and treatment. We will also bring you the latest in lung cancer research and development. We will also take the opportunity to look at thymoma and neuroendocrine tumours and their management and review the optimal lung cancer pathway.
Following on from the success of last year’s debate on health needs assessment, this year we will be debating issue of survivorship and the use of DS1500 forms. Will you be for or against after hearing our two presentations?
In the highly pressurized environment in which we work it is not only important to look after our patients but we have a duty to look after ourselves and our colleagues, support each other and help foster and harness well-being and our own personal development. This year, Ann Burgoyne will be looking at the emotional well-being of our patients and ourselves and, back by popular demand, Drew Povey will be exploring how we look after ourselves and others and giving us added new inspiration and motivation.
Book early for best early bird rates.
The NLCFN is grateful for sponsorship from those companies listed for supporting this event including, but not limited to, AstraZeneca, Chugai, MSD, Pfizer Ltd and Roche. For a full list of all sponsors please see our sponsors page. Read our statement on commercial funding for more information.